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PMH65
IMPACT OF ATYPICAL AGENTS ON OUTCOMES OF CARE IN
SCHIZOPHRENIC PATIENTS
Joyce AT1, Harrison D2, Ollendorf DA1
1PharMetrics, Watertown, MA, USA; 2Pﬁzer Inc, New York, NY, USA
OBJECTIVE: To compare persistence, compliance, and psychi-
atric treatment costs in patients initiating atypical therapies.
METHODS: Medical and pharmacy claims data were used to
compare persistence (days of therapy between ﬁrst and last pre-
scription, allowing therapy gaps <90 days); compliance (days of
medication supplied with total days on therapy); and treatment
costs in schizophrenic adults with claims for atypicals from
March, 2001 to August, 2003 and enrollment for ≥six-months
before and ≥12 months after therapy initiation. One-year psy-
chiatric treatment costs were examined before and after therapy
initiation. Differences in cost ﬂuctuations were tested by uni-
variate techniques. RESULTS: Persistence was approximately 30
days longer for patients receiving ziprasidone (n = 217; 228 days)
than risperidone (n = 831; 193 days) or olanzapine (n = 762; 201
days). Compliance was signiﬁcantly (P < 0.01) higher among
patients receiving ziprasidone (87%) compared with other treat-
ments (78%–80%). Ziprasidone patients had signiﬁcantly larger
decreases (-$6866) in mean annual psychiatric-related costs fol-
lowing therapy initiation than those on risperidone (-$3353; P
= 0.0116) or olanzapine (-$4764; P = 0.0021). The primary
driver of cost savings was reduced hospitalization after treatment
initiation. CONCLUSION: Patients initiated on ziprasidone had
longer persistence, better compliance, and greater decreases in
psychiatric-related costs than those initiated on other atypicals.
MUSCULAR—SKELETAL DISORDERS INCLUDING
CARPAL TUNNEL SYNDROME
PMS1
INCREMENTAL DIRECT COST OF BACK PAIN IN THE UNITED
STATES IN 2001
Balu S,Thomas III J
Purdue University, West Lafayette, IN, USA
OBJECTIVES: Back pain is an expensive medical condition and
direct medical costs associated with back pain are signiﬁcant.
Estimating resource utilization costs for diseases like back pain
based on disease coding have the potential for under-estimation.
The objective of this study was to determine direct costs due 
to back pain in the US population using an incremental cost
approach. METHODS: Analysis of the 2001 Medical Expendi-
ture Panel Survey (MEPS) was conducted. Patients who had back
pain related physician visits or treatments during 2001 were
identiﬁed using International Classiﬁcation of Diseases (ICD-9)
codes. Patients without a back pain diagnosis and without a
claim for back pain were treated as controls. Least squares
regression was used to estimate the incremental cost of back pain
adjusting for age, gender, race, occupation, and co-morbidities
using the Charlson co-morbidity index. Sample data was pro-
jected to the US population and 95 percent conﬁdence limits for
estimates were calculated using the Taylor expansion method.
RESULTS: Prevalence of back pain in the US was 8.3%
(26,167,199) of the total population. Total annual direct costs
for back pain patients were $32,135,937,092 after adjusting for
co-morbidities. Mean annual direct cost for a back pain patient
was $4241.3 (95% CL $3890.8–$4591.8). Ofﬁce-based medical
provider visits (29.4%), in-patient visits (27.1%), and prescribed
medicines (21.3%) were major cost centers for back pain
patients. CONCLUSIONS: With direct medical costs estimated
at more than $32.0 billion in 2001, back pain costs represent a
signiﬁcant amount of health care expenditures. The estimate
obtained was more than twice the magnitude of earlier estimates
based only on expenditures coded for back pain. Potential for
disease cost under estimation may be reduced by using the incre-
mental cost approach.
PMS2
EVALUATION OF AN AUTOMATED SYSTEM FOR PRIOR
AUTHORIZATION—A COX-2 INHIBITOR EXAMPLE
Carroll NV1, Smith JC2, Berringer RA3, Oestreich GL4
1Virginia Commonwealth University School of Pharm, Richmond,VA,
USA; 2Afﬁliated Computer Services, Richmond,VA, USA; 3University
of Pittsburgh, Pittsburgh, PA, USA; 4Missouri Division of Medical
Services, Jefferson City, MO, USA
OBJECTIVES: To evaluate the effectiveness of an automated
prior authorization system (SmartPA) in 1) reducing utiliza-
tion/expenditures of Cox-2 inhibitors; 2) increasing utiliza-
tion/expenditures of Cox-2 substitutes (traditional nonsteroidal
anti-inﬂammatory drugs (NSAIDs), other products for pain or
musculoskeletal conditions, and GI protective agents) to no more
than the decrease seen for Cox-2’s; and 3) decreasing Cox-2 uti-
lization/expenditures more in patients at low risk for GI com-
plications than in patients at high risk. METHODS: The study
used a before and after with control group design. Changes in
utilization/expenditures of Cox-2 inhibitors and Cox-2 substi-
tute products were compared after implementation of SmartPA
in Missouri’s Medicaid plan. The Medicaid plan of an eastern
state that had no PA system for Cox-2’s was used as the control.
Subjects were patients with a claim for a Cox-2 inhibitor in the
12-month baseline period that were continuously enrolled for the
24-month study period. Analyses consisted of comparisons of
means and linear regression. Regressions controlled for differ-
ences in age, gender, risk for GI complications, and severity of
illness. RESULTS: Regression results indicated that increases in
expenditures on Cox-2 inhibitors and GI-protective products
were $178 per patient per year (PPPY) higher and $191 PPPY
higher, respectively, in the control state. Increases in expenditures
on traditional NSAIDs and other pain and musculoskeletal prod-
ucts were $34 PPPY higher in the treatment state. Patients at low
risk for GI complications in the treatment state experienced
greater reductions in expenditures than did those in the high-
risk group. Results were similar for utilization for all of the
above analyses. CONCLUSION: SmartPA was successful in
reducing expenditures/utilization on Cox-2 inhibitors for 
Missouri Medicaid compared to the control, while keeping the
increase in expenditures/utilization for Cox-2 substitutes sub-
stantially lower than this decrease. These effects were concen-
trated among patients at low risk for GI complications.
OBESITY
POB1
COMPARISON OF WEIGHT REDUCTION AND SATISFACTION
OF ORLISTAT AND SIBUTRAMINE
Mekaroonreung S,Auamnoy T,Thaweechotepatara P
Chulalongkorn University, Bangkok,Thailand
OBJECTIVE: The objective of this study was to compare and
evaluate the efﬁcacy and satisfaction of orlistat and sibutramine
treatment in obese female patients at adisorn fort hospital in
2004. METHODS: A cross-sectional experimental study by ran-
domized block design was performed. The population was
women age 18 to 45 those whom wanted to reduce their weight
(bmi > 25) with orlistat or sibutramine under physician control
at adisorn fort hospital, Thailand. Sample was calculated by
cohen’s table, setting alpha = 0.05, beta = 0.2, power 0.80 effect
size = 2, sample size (n) = 40. We administered orlistat (360mg/d)
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or sibutramine (10mg/d) in a randomized, controlled, single-
blind clinical study, and evaluated weight and satisfaction during
six-weeks of this treatment. RESULTS: A total of 40 females 36
+/- 4yr with orlistat; and 40 females, aged 37 +/- 6yr with sibu-
tramine) completed six-weeks on exercise and a controlled-
energy diet. Orlistat was well tolerated, with gastrointestinal
adverse effects as well as inhibiting the assimilation of fat from
the bowel. It was approved for long-term treatment of obesity
while sibutramine acted on the cns to control appetite or enhance
the feeling of saturation. Signiﬁcant body mass index (bmi)
improvement was detected after six-weeks (p < 0.05) in both
groups (p = 0.02, p = 0.04 respectively). Signiﬁcant waist cir-
cumference (wc), but not signiﬁcant hip circumference (hc),
improvement were observed in both groups (p = 0.03, p = 0.14,
p = 0.04, p = 0.21 respectively). Orlistat and sibutramine were
not signiﬁcantly different in terms of weight reduction effect (p
= 0.14). However, patients were more satisﬁed with oristat than
sibutramine (p = 0.02). CONCLUSIONS: Orlistat and sibu-
tramine could signiﬁcantly reduce weight. However, patients
were more satisﬁed with orlistat than sibutramine.
POB2
RECENT TRENDS AND A FUTURE FORECAST OF
POPULATION BODY MASS INDEX LEVELS IN THE UNITED
KINGDOM
Woehl A1, Currie CJ2
1Kiel University, Kiel, Germany; 2Cardiff University, Cardiff, UK
OBJECTIVE: Patterns of obesity are an important public health
consideration. The purpose of this study was to determine the
past and future population trends of obesity in the UK (UK).
METHODS: Data describing body mass index (BMI) were
abstracted from the English Health Survey’s from 1991 to 2002,
inclusive. The UK was assumed to follow the same pattern of
change in body composition as England. The distributional
pattern of BMI was determined and age and sex speciﬁc changes
in the distribution described over the period. Data were stan-
dardized to the UK population in 2001. Ethnicity was accounted
for in the forecast using general linear models for age and sex
speciﬁc groups applied to government forecasts of future demog-
raphy. RESULTS: BMI increased by a mean value of 1.21kg/m2
(standard error of the mean (SEM) 0.105 to 0.044 [≥18 years]),
equivalent to an annual increase of 0.11kg/m2 per year (95% CI
0.106 to 0.123). BMI in women increased on average from 25.6
to 26.8kg/m2, and men’s from 25.9 to 27.1kg/m2. This varied
by age and sex. The annual change in mean BMI was linear in
every age group. In 1991 and 2002 the proportion of overweight
(≥25.0 to <30.0kg/m2) and obese (≥30.0kg/m2) people in the
population rose from 29.5% and 12.0%, to 31.3% and 18.4%,
respectively. The number of overweight and obese people in the
general population in 2004 was estimated to be 31.2 million
people (52.6%), increasing to 38.0 million people (62.0%) in ten
years time, an increase of 6.8 million people. CONCLUSION: If
reliable, this estimate clearly represents a serious public health
challenge.
POB3
PREVALENCE TRENDS OF OVERWEIGHT AND OBESITY AND
TREATMENT PATTERNS FOR WEIGHT CONTROL IN THE US
POPULATION
Vo L,Valiyeva E, Shin HC, Suh DC, Barone JA
Rutgers University, Piscataway, NJ, USA
OBJECTIVES: To assess epidemiologic trends of overweight and
obesity and to examine treatment patterns to control weight in
children/adolescents aged 2–19 years and for adults ≥20 years
old. METHODS: The Third National Health and Nutrition
Examination Survey (NHANES III) conducted in 1988–1994
and NHANES 2001–2002 were used. Children/adolescents 
were classiﬁed as at risk for overweight if body mass index (BMI)
was ≥85th–<95th percentile and as overweight if BMI was at
≥95th percentile of the sex-speciﬁc BMI for age growth charts.
Adults were categorized as overweight (BMI 25.0–29.9) or obese
(BMI ≥ 30.0). Duration of physical activity was calculated 
using leisure-time physical activity to assess compliance of
CDC/ASCM recommendations. SAS and SUDAAN software
were employed to account for the complex survey design.
RESULTS: The proportions of children/adolescents at risk for
overweight or overweight increased from 13.1% to 14.5% 
and from 11.1% to 15.5%, respectively, between 1988–1994
and 2001–2002. The prevalence of overweight and obesity for
adults also increased from 32.8% to 35.2% and from 22.3% to
30.2%. Prevalence of diabetes in overweight and obese adults
slightly increased between 1988–1994 (5.5%, 10.0% respec-
tively) and 2001–2002 (6.1%, 10.6%). However, LDL ≥ 130
mg/dL was less prevalent in 2001–2002 (53.4% to 41.8% 
for overweight and 54.0% to 41.0% for obesity). Overall,
10.3% of overweight and 14.9% of obese adults used liquid diet
formula, prescription drugs, non-prescription drugs, laxatives or
vomiting to control weight in 2001–2002. Only 1% of over-
weight and 3% of obese adults took prescribed diet pills. About
47% of overweight and 43% of obese adults either took med-
ications or complied with physical activity recommended by
CDC/ASCM to control weight. CONCLUSIONS: Overweight
and obesity have become more prevalent in the US population
during the past decade. However, very few patients took med-
ications prescribed by their physicians to lose or control their
weight.
POB4
RELIABLE MEASUREMENT OF OBESITY: RISK OF VASCULAR
DISEASE COMPLICATIONS AS A FUNCTION OF BODY MASS
INDEX AND WAIST-TO- HIP RATIO
Woehl A1, Currie CJ2, McEwan P2, Peters JR3
1Kiel University, Kiel, Germany; 2Cardiff University, Cardiff, UK;
3University Hospital of Wales, Cardiff, UK
BMI is widely used to measure obesity in outcome studies, but
other easily collected measures are available to characterise
bodily shape. OBJECTIVE: The objective of this study was to
determine whether BMI and waist-to-hip ratio (W:H-R), as stan-
dard measures of obesity, collectively better explained the likeli-
hood of obesity-related complications. METHODS: This
retrospective study used data from the England Health Survey, a
national representative survey of the general population. Data
describing BMI, obesity related diseases and other anthropo-
metric measurements were abstracted from the survey 1991 to
1994, and 1997 to 2002. Using this data, a model was devel-
oped to account for various factors that could effect the devel-
opment of obesity related diseases: diabetes, stroke, heart attack,
hypertension and other vascular diseases. Using logistic regres-
sion, the association of between BMI categories further broken
down by W:H-R categories was determined. The results were
standardized for age, sex and ethnicity to generate standardized
odds ratios comparing the accuracy of different anthropometric
measurements and its combinations to predict obesity related
diseases. RESULTS: BMI and W:H-R were independent predic-
tors of disease in obesity. Using both these measures a more
precise prediction of the likelihood of developing obesity related
complications. Odds ratios in the group with the highest BMI of
the sample varied between 1.6 and 2.8 conditional on their W:
H-R. Patients with a medium BMI but high W:H-R had a higher
relative risk (odds ratio 1.8) than patients with a high BMI but
